Evidence map›Paper›PMID 36171407›Full record

ArticleParasitology research2022

The antimicrobial peptides LL-37, KR-20, FK-13 and KR-12 inhibit the growth of a sensitive and a metronidazole-resistant strain of Trichomonas vaginalis.

María G Ramírez-Ledesma, Mayra C Rodríguez, Nayeli Alva-Murillo, Eva E Avila

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

María G Ramírez-LedesmaBiology Department, DCNE, Universidad de Guanajuato, Guanajuato, Guanajuato, Mexico.
Mayra C RodríguezBiology Department, DCNE, Universidad de Guanajuato, Guanajuato, Guanajuato, Mexico.
Nayeli Alva-MurilloBiology Department, DCNE, Universidad de Guanajuato, Guanajuato, Guanajuato, Mexico.
Eva E AvilaBiology Department, DCNE, Universidad de Guanajuato, Guanajuato, Guanajuato, Mexico. edilia@ugto.mx.ORCID http://orcid.org/0000-0003-2011-688X
Universidad de Guanajuato · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The parasite Trichomonas vaginalis is the aetiologic agent of trichomoniasis, the most common non-viral sexually transmitted disease worldwide. This infection often remains asymptomatic and is related to several health complications. The traditional treatment for trichomoniasis uses drugs of the 5-nitroimidazole family, such as metronidazole; however, scientific reports indicate an increasing number of drug-resistant strains. Antimicrobial peptides could be an alternative or complementary treatment. In this sense, one attractive candidate is the human cathelicidin, being LL-37 its active form. LL-37 possesses microbicidal activity against many microorganisms such as bacteria, Candida albicans, and Entamoeba histolytica. Shorter sequences derived from this peptide, such as KR-20, FK-13 and KR-12, have been shown to possess a higher microbicidal effect than LL-37. In this study, we determined the activity of LL-37 and its derivatives against T. vaginalis, which was unknown. The results showed that the four peptides (LL-37, KR-20, FK-13-NH

Indexed as

Antiprotozoal AgentsTrichomonas InfectionsTrichomonas vaginalisAntimicrobial PeptidesDrug ResistanceHumansMetronidazoleNitroimidazoles4-nitroimidazoleAntimicrobial PeptidesAntiprotozoal AgentsMetronidazoleNitroimidazolesAntimicrobial peptidesHuman cathelicidinLL-37MetronidazoleParasitesTrichomonas vaginalis

Identifiers

PMID36171407
OpenAlexW4297521038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.